Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe
Investigators initiated this multicenter phase II prospective trial to analyse feasibility
(toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised
prostate cancer, who are ineligible for the "PREFERE trial" under the hypothesis that the
ratio of patients with late toxicity ≥ grade 2 after 1 year amounts 2,8% and is significant
lower than 17.5%.